亚虹医药(688176.SH)发布半年度业绩，归母净亏损1.62亿元

Group 1 - The company reported a revenue of 130 million yuan for the first half of 2025, representing a year-on-year growth of 61.80% [1] - The net profit attributable to shareholders was a loss of 162 million yuan [1] - The non-recurring net profit was a loss of 177 million yuan, with a basic earnings per share of -0.29 yuan [1]